Golfyeti,
Yes eye popping numbers for that Spark deal. What a week for adeno-associated virus (AAV) biotech in the news! In addition to Spark, Voyager and Abbvie's were in the news this week for their deal to use Voyager's AAV-mediated vectorized antibody approach. That's pre-clinical, but still very cool stuff.
BearDownAZ